SB 535 requires most health benefit plans offered to large and small employers and individual market policies in Oregon to cover a broad set of infertility-related services and treatments. Covered services include diagnostic testing, medications, procedures, assisted reproductive technology, in vitro fertilization, embryo and egg retrievals, cryopreservation, embryo transfer, intrauterine insemination, and related laboratory and surgical services when recommended by a licensed treating practitioner and consistent with professional guidelines. The bill defines infertility broadly, including both traditional clinical infertility and an individual’s inability to reproduce without medical intervention, and it requires coverage to extend to covered spouses and dependents on the same basis as other pregnancy-related benefits.
The bill also limits insurers’ ability to impose exclusions, restrictions, or step-therapy requirements on covered infertility services, while carving out an exemption for certain insurers described in existing law. For those exempt insurers, the Department of Consumer and Business Services must create a reimbursement program for specified fertility services, funded through a new Market Equity Fund. SB 535 also directs the Oregon Health Authority and DCBS to study access to fertility and reproductive endocrinology services, including barriers and inequities by race, ethnicity, gender identity, sexual orientation, income, marital status, immigration status, and disability, and to report recommendations to the Legislature by February 15, 2027.
In addition to the coverage mandate, the bill amends Oregon insurance statutes to support the new program and funding structure. It changes how certain assessments collected from insurers are used, redirecting specified amounts into the Market Equity Fund rather than the general fund, and authorizes DCBS to contract with a third-party administrator or insurer to process reimbursement claims. The coverage provisions apply to policies issued, renewed, or extended on or after January 1, 2026, and the bill declares an emergency, making it effective on passage.
The general sentiment reflected in the available vote history is favorable, with the Senate committee voting 3-2 to do pass with amendments and refer the bill to Ways and Means by prior reference. The bill’s findings emphasize health benefits, reduced disparities, and improved outcomes for parents and children, suggesting a policy rationale centered on access and equity. No committee transcript is available in the provided materials, so the broader discussion record is limited.
The main point of contention appears to be cost and scope. The bill requires extensive infertility coverage and creates a reimbursement mechanism for exempt insurers, which likely raises concerns about premium impacts, administrative complexity, and the use of insurer assessments. The exemption for certain insurers and the separate reimbursement program indicate an effort to balance broader coverage goals with existing market structures, but those distinctions may also be a source of debate among insurers, employers, and policymakers concerned about mandates and funding.
SB 535 would add a new infertility coverage mandate to Oregon’s Insurance Code and amend related statutes governing insurer assessments and fund usage. It would require most regulated health benefit plans to cover specified fertility and reproductive endocrinology services, prohibit certain coverage limitations, and create a state reimbursement program for services not covered by exempt insurers. The bill also establishes the Market Equity Fund and redirects a portion of insurer assessments to finance administration of that program, while directing OHA and DCBS to conduct a study and report on access and equity in fertility care.
The available voting record suggests cautious support: the Senate committee approved the bill 3-2 with amendments, indicating majority backing but not unanimity. The bill’s framing around infertility access, reproductive health, and equity suggests generally positive policy sentiment among supporters. At the same time, the split vote implies some concern about the breadth of the mandate, fiscal effects, and implementation details.
The likely areas of contention are the cost of mandated fertility coverage, the extent of required services, and how the bill treats exempt insurers. Opponents or skeptics may object to requiring coverage for IVF and related services, the potential premium impact on employers and individuals, and the use of insurer assessments to fund reimbursement. Supporters appear focused on reducing barriers and disparities in access, including for LGBTQ+ individuals, people of color, and others facing infertility care inequities.